Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) announced on September 23 that the phase II clinical trial of the American registration project (F0026 project) for the treatment of fresh red nevus developed by the company has recently completed the first subject enrollment in the USA.
Haimobofen is the world's first photodynamic drug for the treatment of fresh red nevi, integrating new drug targets, new compounds, and new indications into one new drug. As a second-generation photosensitizer, Haimobofen has characteristics of stable compound structure, low phototoxicity, and its use in the treatment of fresh red nevi is included in the People's Medical Publishing House's "Dermatology" (Ninth Edition) textbook. Photodynamic therapy with Haimobofen in the treatment of fresh red nevi has significant advantages such as precise efficacy, uniform lesion disappearance, rapid metabolism, short avoiding light period, low incidence of scarring, and very rare recurrence after cure.
